Advertise on podcast: The Myeloma Minutes

This episode explores the latest advances in myeloma treatment, explaining how the PERSEUS regimen combines four drugs, stem cell transplant and personalised maintenance to help patients achieve deeper, longer-lasting remissions. 📌Key Takeaways:  Could remission last 10 years or more?  Four drugs, better results - what has changed?  Side effects matter: why your treatment can be adjusted.  For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Could the right treatment pace make all the difference to living well with myeloma?  Professor Gordon Cook explores frailty in myeloma, explaining why it is more than age, how fitness can change during treatment, and why treatment should be tailored to the individual. 📌Key Takeaways:  Frailty is dynamic - it can change.  Age alone doesn't tell the whole story.  Myeloma treatment isn't a sprint - it's a marathon. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explores the realities of living with multiple myeloma, from treatment and managing symptoms to maintaining quality of life and finding confidence beyond the diagnosis.  📌Key Takeaways:  Myeloma changes life - but it doesn’t have to define it.  Small changes can make a big difference to wellbeing.  You can still plan, adapt and look forward. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explores the latest breakthroughs from the world's leading myeloma conferences, explaining how new research and clinical trials could shape future treatment and improve patient care with Charlotte. 📌Key Takeaways:  Discover the newest treatments that could transform myeloma care in the years ahead.  Find out why clinical trials today become tomorrow’s standard treatments.  Hear how global collaboration is bringing safer, more effective therapies closer to patients. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explains when DT-PACE chemotherapy is used in myeloma, how it works, what patients can expect during treatment, and why it remains an important bridge to newer therapies. 📌Key Takeaways:  Why use older chemotherapy? Sometimes it's the fastest way to get myeloma back under control.  DT-PACE is a bridge - helping patients reach treatments like stem cell transplant or CAR T-cell therapy.  The treatment is intensive, but careful monitoring helps manage side effects and maximise its benefits.For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Experts discuss the approval of the new DVRD four-drug treatment for newly diagnosed myeloma patients who are not eligible for a stem cell transplant, exploring its benefits, risks and how treatment decisions are personalised. 📌Key Takeaways:  New four-drug treatment now available in England and Wales Deeper remissions and longer disease control for many patients  Why the “best” treatment depends on you, not just the disease  For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Author Jonathan Gluck shares his deeply personal experience of living with myeloma, reflecting on diagnosis, uncertainty, treatment, resilience and what it means to build a life alongside cancer. 📌Key Takeaways:  How do you live with uncertainty? Jonathan shares the lessons myeloma taught him.  A diagnosis can change your life - but it doesn’t have to define it.  One patient’s story of resilience, perspective and finding hope in unexpected places.Find Jonathan's book here: Amazon UK For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explores why people with myeloma are more vulnerable to infection, how treatments affect immunity, and the practical steps patients and carers can take to stay well. 📌Key Takeaways: Myeloma and its treatments can weaken the immune system - but the risk changes over time. Fever, coughs or feeling “not quite right” should never be ignored - early treatment matters.From vaccines to exercise and preventative antibiotics, small steps can make a big difference. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explains why people with myeloma are at higher risk of blood clots, how blood thinners help, and the warning signs patients and carers should never ignore. 📌Key Takeaways: Myeloma and some myeloma treatments can increase the risk of dangerous blood clots. Simple steps like staying hydrated, keeping mobile and taking blood thinners correctly really matter. Leg swelling, chest pain or sudden breathlessness should never be ignored : Fast treatment saves lives. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explores why pain happens in myeloma, how it affects daily life, and the many ways it can be managed - from painkillers to specialist support. 📌Key Takeaways: Myeloma pain is common - but it can almost always be improved with the right approach. Pain relief isn’t just tablets - treatments, radiotherapy and targeted procedures all play a role. Uncontrolled pain affects everything - so speak up early and often to get the help you need. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explains minimal residual disease (MRD) - what it is, how it’s measured, and how it could shape more personalised myeloma treatment in the future. 📌Key Takeaways: Even when blood tests look ‘normal’, tiny amounts of myeloma can still remain - MRD helps find it. Reaching MRD negativity is a powerful sign - it often means longer, deeper remission. In the future, MRD could decide when to stop, reduce or restart treatment - but we’re not quite there yet. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode breaks down common blood test results in myeloma, helping patients and carers understand what the numbers mean, what matters most, and when to worry (and when not to). 📌Key Takeaways: Not all ‘red’ results are bad - trends over time matter more than a single number. Three key numbers to watch: haemoglobin, neutrophils and platelets. Blood tests are your roadmap - guiding treatment, safety and how you’re really doing. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Meera shares her powerful 15-year journey with multiple myeloma — from diagnosis during pregnancy to stem cell transplant, maintenance therapy and ultimately CAR-T treatment leading to remission.   📌Key Takeaways: CAR-T can work fast! Mira’s light chains became undetectable within weeks. Relapse doesn’t mean the end of options: new treatments are changing what’s possible. You are not alone: sharing real patient stories helps break the isolation of myeloma. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

In this episode Doctors Jam & Sally explain CAR-T cell therapy for myeloma - how it works, what the treatment journey looks like, the potential side effects, and why it offers hope for longer treatment-free time. 📌Key Takeaways: Your own immune cells can be re-engineered to find and destroy myeloma - a truly personalised treatment. After CAR-T, many patients can have months or years off regular therapy. It’s powerful and promising - but not everyone can access it yet, and it doesn’t work for all patients. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explains the new NICE-approved combination of belantamab, pomalidomide and dexamethasone for people whose myeloma has relapsed after first-line treatment, including benefits, side effects and how treatment decisions are made. 📌Key Takeaways: This new combination can keep myeloma under control for nearly three years after first relapse. Eye side effects are common but closely monitored, reversible and manageable with dose changes. Patients now have real choice between tablet-based or injection-based combinations after relapse. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.